P-154 A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015
Titel:
P-154 A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015
Auteur:
Tabernero, J. Cohen, D. Van Cutsem, E. Janjigian, Y. Bang, Y. Qin, S. Wang, A. Hawk, N. Shih, C. Bhagia, P. Shitara, K.